Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor: Pivotal Results from OrigAMI-4

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, describes historical outcomes for patients with relapsed or recurrent metastatic head and neck squamous cell carcinoma (HNSCC) who progress after anti-PD-(L)1 therapy and platinum-based chemotherapy.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses the biological rationale for targeting epidermal growth factor receptor (EGFR) and MET in head and neck squamous cell carcinoma (HNSCC).